Omega Therapeutics (Omega Therapeutics) 3-Year ROIIC % : -56.09% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Omega Therapeutics 3-Year ROIIC %?

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Omega Therapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2023 was -56.09%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Omega Therapeutics's 3-Year ROIIC % or its related term are showing as below:

OMGA's 3-Year ROIIC % is ranked worse than
62.98% of 1418 companies
in the Biotechnology industry
Industry Median: -13.845 vs OMGA: -56.09

Omega Therapeutics 3-Year ROIIC % Historical Data

The historical data trend for Omega Therapeutics's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omega Therapeutics 3-Year ROIIC % Chart

Omega Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

3-Year ROIIC %

-636.80

-56.09

Omega Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
3-Year ROIIC %	Get a 7-Day Free Trial													-	-	-	-56.09	-

Competitive Comparison of Omega Therapeutics's 3-Year ROIIC %

For the Biotechnology subindustry, Omega Therapeutics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Omega Therapeutics's 3-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omega Therapeutics's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Omega Therapeutics's 3-Year ROIIC % falls into.

Omega Therapeutics 3-Year ROIIC % Calculation

Omega Therapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

3-Year ROIIC %	=	3-Year Incremental Net Operating Profit After Taxes (NOPAT)^**	/	3-Year Incremental Invested Capital^**
	=	( -100.261 (Dec. 2023) - -28.645 (Dec. 2020) )	/	( 136.236 (Dec. 2023) - 8.563 (Dec. 2020) )
	=	-71.616	/	127.673
	=	-56.09%^***

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.

Omega Therapeutics (NAS:OMGA) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.

Omega Therapeutics 3-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Omega Therapeutics's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.

Omega Therapeutics (Omega Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omega Therapeutics Inc (NAS:OMGA) » Definitions » 3-Year ROIIC %

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 Acorn Park Drive, Cambridge, MA, USA, 02140

Website

https://www.omegatherapeutics.com

Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using the epigenomic controllers, Omega is seeking to transform the practice of human medicine through highly selective and direct control of the human genome to treat and cure disease. It primarily operates in the U.S.

Executives

Michelle C Werner	director	C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Christian S Schade	director	MEDAREX, 707 STATE ROAD, PRINCETON NJ 08540
Richard A Young	director, 10 percent owner	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE SUITE 300, CAMBRIDGE MA 02139
Flagship Pioneering Special Opportunities Fund Ii General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Pioneering Fund Vii, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Pioneering Fund Vii General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Rainer J. Boehm	director	C/O HUMANIGEN, INC., 1000 MARINA BOULEVARD, SUITE 250, BRISBANE CA 94005-1878
Joshua Reed	officer: Chief Financial Officer	C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421
Kevin Mcmanus	officer: Chief Human Resources Officer	C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Ling Zeng	officer: See Remarks	C/O DICERNA PHARMACEUTICALS, INC., 33 HAYDEN AVENUE, LEXINGTON MA 02421
Yan Moore	officer: Chief Medical Officer	C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
David A Berry	director	C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142
Flagship Ventures Fund V General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Roger Sawhney	officer: Chief Financial Officer	C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Flagship Pioneering Fund Vi General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142